Cardiac resynchronization therapy device management

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief:: Nehal Eid, M.D.[2]


Device management

Post-implantation management of cardiac resynchronization therapy (CRT) focuses on maintaining effective resynchronization, detecting device- and heart-failure–related deterioration, managing apparent non-response, and planning generator replacement, imaging, infection care, and goals-of-care discussions. Initial implantation technique, primary CRT indications, and primary conduction-system pacing strategies are addressed elsewhere.

Routine device surveillance and programming

Area Device-management approach
Effective biventricular pacing Aim for ≥98% effective biventricular (BiV) pacing. Device-reported pacing percentages may overestimate true resynchronization when triggered LV pacing, fusion, or pseudofusion is present; review stored electrograms and consider ambulatory ECG monitoring when effective pacing is uncertain.[1][2]
Causes of reduced effective pacing Identify and correct atrial tachyarrhythmias, premature ventricular contractions, inappropriate AV timing, intermittent LV capture, and lead-related problems.[1]
AV and VV timing Routine AV/VV optimization is not required in all recipients; the SMART-AV trial found no benefit of echocardiographic or algorithmic AV-delay optimization over a fixed 120-ms AV delay in the general CRT population.[3] A pooled analysis of SMART-AV and SMART-CRT found improved CRT response with AV optimization in patients with interventricular delay ≥70 ms.[4] Consider electrocardiographic, echocardiographic, or device-algorithm–based optimization in patients with persistent symptoms, suboptimal hemodynamics, apparent non-response, or prolonged interventricular delay.
LV pacing vector and multipoint pacing Quadripolar LV leads have lower rates of lead-related complications, lead deactivation, and lead dislodgement than bipolar leads and are associated with improved survival in meta-analysis.[5] Reprogramming a quadripolar LV vector may address phrenic nerve stimulation or high pacing thresholds. Multipoint pacing may be considered selectively, with attention to battery longevity and uncertain outcome benefit.

Remote monitoring and heart-failure surveillance

Remote monitoring is standard care for patients with CRT devices. The remote-monitoring strategy should maintain connectivity and use individualized alerts for lead integrity, battery status, low BiV pacing, and clinically relevant atrial arrhythmias. Remote review of heart-failure diagnostics is reasonable when linked to a defined clinical response pathway.[6]

Minimum follow-up intervals include:

  • Within 72 hours after implantation: in-person assessment.
  • At 2–12 weeks after implantation: in-person assessment.
  • Every 3–12 months for CRT-P and every 3–6 months for CRT-D: in-person or remote assessment.
  • Annually until battery depletion: in-person assessment.
  • Every 1–3 months when battery depletion is approaching: in-person or remote assessment.[7]

With consistent continuous connectivity and no recent alerts or active cardiac comorbidity requiring closer review, in-person visits may be extended to every 24 months (Class IIa, LOE B-R).[6]

Modern CRT devices may integrate activity, heart rate, respiratory rate, heart sounds, and impedance data. Multiparameter alerts can identify increased risk of heart-failure events and may support intervention within a defined clinical response pathway. A meta-analysis of six randomized trials found multiparameter-guided heart-failure management reduced the composite of all-cause death or heart-failure hospitalization (incidence rate ratio 0.83, 95% CI 0.71–0.99).[8] Thoracic impedance alone should not be used to manage congestion.[9]

Perform a follow-up echocardiogram approximately 3–12 months after implantation to assess LV remodeling, ejection fraction, ventricular volumes, and mitral regurgitation (Class I, LOE B-NR). Subsequent imaging should be directed by symptoms, device findings, or a change in clinical status.[9]

Management of apparent CRT non-response

Apparent non-response should prompt a structured reassessment rather than immediate device revision.

  1. Confirm true effective BiV pacing and exclude fusion, pseudofusion, intermittent LV capture, or low pacing delivery.
  2. Review device interrogation for lead thresholds, sensing, impedance trends, phrenic stimulation, arrhythmia burden, and programmed AV/VV timing.
  3. Identify and correct competing causes, including atrial fibrillation, frequent ventricular ectopy, progressive ischemia, valvular disease, and suboptimal guideline-directed medical therapy.
  4. Consider PVC-directed therapy, including catheter ablation, when PVC burden is high (commonly >10%–15%) and compromises effective BiV pacing.[1]
  5. Reassess LV lead position and myocardial substrate when clinically indicated.
  6. Refer persistent non-responders to a multidisciplinary heart-failure/electrophysiology service for consideration of optimization, arrhythmia treatment, lead revision, or alternative resynchronization strategies.[9]

In patients with AF, inadequate effective BiV pacing despite medical management should trigger reassessment of rate or rhythm control. Atrioventricular node ablation may improve pacing delivery in selected patients, but outcome evidence is not uniform across trials. The APAF-CRT trial showed a mortality benefit for AV-junction ablation plus de novo CRT implantation versus pharmacological rate control in patients with permanent AF and narrow QRS (≤110 ms).[10] In contrast, the CAAN-AF trial found no benefit of AV-node ablation versus medical rate control in patients with HFrEF, permanent AF, and pre-existing CRT-D.[11] These trials addressed different clinical questions and should not be directly compared. Decisions should be individualized according to pacing delivery, symptoms, ventricular function, procedural risk, and patient goals.

Generator replacement and device revision

At elective generator replacement, continue BiV pacing in patients with heart failure with improved ejection fraction or other evidence of clinical benefit from CRT. Evaluate lead performance, pacing thresholds, anticipated battery longevity, procedural risk, and the ongoing need for defibrillator therapy.[9]

In selected patients at elevated risk of CIED infection who undergo replacement or upgrade, consider evidence-based infection-prevention measures, including an absorbable antibiotic-eluting envelope where appropriate. In the WRAP-IT trial, the envelope reduced major CIED infections by 40% over 12 months in patients undergoing revision, replacement, upgrade, or de novo CRT-D implantation.[12][13]

Replacement of a CRT-defibrillator (CRT-D) with a CRT-pacemaker (CRT-P) should be individualized through shared decision-making. Consider prior appropriate ICD therapies, residual ventricular-arrhythmia risk, current LVEF, lead status, comorbidity, life expectancy, and patient preferences. In patients with LVEF recovery after primary-prevention CRT-D implantation, the 2025 appropriate-use criteria rate downgrade to CRT-P as “May Be Appropriate.”[14]

Device infection

Suspected cardiac implantable electronic device infection requires prompt electrophysiology and infectious-disease assessment. Definite pocket infection, lead infection, or CIED-related infective endocarditis generally requires complete system extraction plus culture-directed antimicrobial therapy; early extraction after diagnosis is associated with better outcomes.[13]

Empiric antibiotic therapy should include a vancomycin- or daptomycin-containing regimen because methicillin-resistant staphylococci are common causes of CIED infection; subsequent treatment should be culture-directed.[15] Recommended antimicrobial durations after extraction are 7 days for pocket erosion without purulence, 10 days for pocket infection with purulence, at least 2 weeks for bloodstream infection without valve involvement, and 4–6 weeks of parenteral therapy for valvular infective endocarditis.[13]

Reimplantation should occur only after infection control and negative blood cultures for at least 72 hours; in patients with valvular infective endocarditis, reimplantation should be delayed for at least 14 days after extraction. In selected patients with an ongoing indication for defibrillator protection, a wearable cardioverter-defibrillator may serve as a bridge to permanent device reimplantation. A contralateral implantation site is preferred when feasible. Long-term antimicrobial suppression without extraction is generally reserved for patients with prohibitive extraction risk or palliative goals.[13][16][17]

Magnetic resonance imaging

Before magnetic resonance imaging (MRI), verify the generator and every lead, including lead status and MRI-conditional labeling. An MRI-conditional system requires all components to meet the manufacturer’s conditions. Perform pre-scan interrogation, manufacturer-specific MRI programming, continuous physiologic monitoring during the scan, and post-scan interrogation.[18][19]

MRI in selected patients with non-conditional transvenous systems may be performed under an experienced institutional protocol after individualized risk assessment. Fractured, epicardial, or abandoned leads require particular caution and local protocol review.[18]

Goals of care and device deactivation

Discuss device management as part of advance-care planning at implantation and revisit it with clinical deterioration, recurrent hospitalization, transition to advanced heart-failure therapies, or palliative care. In CRT-D recipients, deactivation of ICD shock therapy may prevent distressing shocks near the end of life when consistent with informed patient preferences.[7]

Magnet application over a CRT-D generator can temporarily suspend tachyarrhythmia detection and therapy when formal reprogramming is not immediately available. Magnet response is programmable and may be disabled; Biotronik ICDs automatically re-enable tachyarrhythmia detection after 8 hours of continuous magnet application and, unlike other manufacturers, do not produce an audible tone when a magnet is applied. Confirm manufacturer- and programming-specific magnet behavior before relying on this approach. Pacing function is not affected by magnet application to an ICD/CRT-D.[20]

Do not automatically deactivate CRT pacing when ICD therapies are turned off. Withdrawal of BiV pacing can worsen heart-failure symptoms, particularly in pacing-dependent patients; decisions require individualized discussion, informed consent, and coordination among electrophysiology, heart-failure, and palliative-care teams.[21][22]

References

  1. ↑ 1.0 1.1 1.2 Madhavan M, Mulpuru SK, McLeod CJ, Cha YM, Friedman PA (2017). "Advances and Future Directions In Cardiac Pacemakers: Part 2 of a 2-Part Series". Journal of the American College of Cardiology. 69 (2): 211–235. doi:10.1016/j.jacc.2016.10.064.
  2. ↑ Koplan BA, Kaplan AJ, Weiner S; et al. (2009). "Heart Failure Decompensation and All-Cause Mortality in Relation to Percent Biventricular Pacing in Patients With Heart Failure: Is a Goal of 100% Biventricular Pacing Necessary?". Journal of the American College of Cardiology. 53 (4): 355–360. doi:10.1016/j.jacc.2008.09.043.
  3. ↑ Ellenbogen KA, Gold MR, Meyer TE; et al. (2010). "Primary Results From the SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) Trial". Circulation. 122 (25): 2660–2668. doi:10.1161/CIRCULATIONAHA.110.992552.
  4. ↑ Gold MR, Auricchio A, Leclercq C; et al. (2024). "Atrioventricular Optimization Improves Cardiac Resynchronization Response in Patients With Long Interventricular Electrical Delays: A Pooled Analysis of the SMART-AV and SMART-CRT Trials". Heart Rhythm. 21 (9): 1686–1694. doi:10.1016/j.hrthm.2024.03.1783.
  5. ↑ Erath JW, Benz AP, Hohnloser SH, Vamos M (2019). "Clinical Outcomes After Implantation of Quadripolar Compared to Bipolar Left Ventricular Leads in Patients Undergoing Cardiac Resynchronization Therapy: A Systematic Review and Meta-Analysis". Europace. 21 (10): 1543–1553. doi:10.1093/europace/euz190.
  6. ↑ 6.0 6.1 Ferrick AM, Raj SR, Deneke T; et al. (2023). "2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic". Heart Rhythm. 20 (9): e92–e144. doi:10.1016/j.hrthm.2023.03.1525.
  7. ↑ 7.0 7.1 Epstein AE, DiMarco JP, Ellenbogen KA; et al. (2013). "2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities". Journal of the American College of Cardiology. 61 (3): e6–e75. doi:10.1016/j.jacc.2012.11.007.
  8. ↑ Zito A, Restivo A, Ciliberti G; et al. (2023). "Heart Failure Management Guided by Remote Multiparameter Monitoring: A Meta-Analysis". International Journal of Cardiology. 388: 131163. doi:10.1016/j.ijcard.2023.131163.
  9. ↑ 9.0 9.1 9.2 9.3 Chung MK, Patton KK, Lau CP; et al. (2023). "2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure". Heart Rhythm. 20 (9): e17–e91. doi:10.1016/j.hrthm.2023.03.1538.
  10. ↑ Brignole M, Pentimalli F, Palmisano P; et al. (2021). "AV Junction Ablation and Cardiac Resynchronization for Patients With Permanent Atrial Fibrillation and Narrow QRS: The APAF-CRT Mortality Trial". European Heart Journal. 42 (46): 4731–4739. doi:10.1093/eurheartj/ehab569.
  11. ↑ Sanders P, Ariyaratnam JP, Stiles MK; et al. (2026). "Cardiac Resynchronization Therapy With or Without Atrioventricular Node Ablation in Atrial Fibrillation: The CAAN-AF Trial". European Heart Journal. doi:10.1093/eurheartj/ehag206.
  12. ↑ Tarakji KG, Mittal S, Kennergren C; et al. (2019). "Antibacterial Envelope to Prevent Cardiac Implantable Device Infection". New England Journal of Medicine. 380 (20): 1895–1905. doi:10.1056/NEJMoa1901111.
  13. ↑ 13.0 13.1 13.2 13.3 Baddour LM, Esquer Garrigos Z, Rizwan Sohail M; et al. (2024). "Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association". Circulation. 149 (2): e201–e216. doi:10.1161/CIR.0000000000001187.
  14. ↑ Russo AM, Desai MY, Do MM; et al. (2025). "ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing". Journal of the American College of Cardiology. 85 (11): 1213–1285. doi:10.1016/j.jacc.2024.11.023.
  15. ↑ Palmeri NO, Kramer DB, Karchmer AW, Zimetbaum PJ (2021). "A Review of Cardiac Implantable Electronic Device Infections for the Practicing Electrophysiologist". JACC: Clinical Electrophysiology. 7 (6): 811–828. doi:10.1016/j.jacep.2020.10.020.
  16. ↑ Chesdachai S, Esquer Garrigos Z, DeSimone CV, DeSimone DC, Baddour LM (2024). "Infective Endocarditis Involving Implanted Cardiac Electronic Devices: JACC Focus Seminar 1/4". Journal of the American College of Cardiology. 83 (14): 1326–1337. doi:10.1016/j.jacc.2023.11.036.
  17. ↑ Kusumoto FM, Schoenfeld MH, Wilkoff BL; et al. (2017). "2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction". Heart Rhythm. 14 (12): e503–e551. doi:10.1016/j.hrthm.2017.09.001.
  18. ↑ 18.0 18.1 Indik JH, Gimbel JR, Abe H; et al. (2017). "2017 HRS Expert Consensus Statement on Magnetic Resonance Imaging and Radiation Exposure in Patients With Cardiovascular Implantable Electronic Devices". Heart Rhythm. 14 (7): e97–e153. doi:10.1016/j.hrthm.2017.04.025.
  19. ↑ American College of Radiology. American College of Radiology Manual on MR Safety: 2024 Update and Revisions. 2024.
  20. ↑ Wan EY, Rogers AJ, Lavelle M; et al. (2024). "Periprocedural Management and Multidisciplinary Care Pathways for Patients With Cardiac Implantable Electronic Devices: A Scientific Statement From the American Heart Association". Circulation. 150 (8): e183–e196. doi:10.1161/CIR.0000000000001264.
  21. ↑ Graven LJ, Kitko L, Abshire Saylor M; et al. (2025). "Palliative Care and Advanced Cardiovascular Disease in Adults: Not Just End-of-Life Care: A Scientific Statement From the American Heart Association". Circulation. 151 (21): e1030–e1042. doi:10.1161/CIR.0000000000001323.
  22. ↑ Kusumoto FM, Schoenfeld MH, Barrett C; et al. (2019). "2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay". Journal of the American College of Cardiology. 74 (7): e51–e156. doi:10.1016/j.jacc.2018.10.044.

```

Retrieved from "https://www.wikidoc.org/index.php?title=Cardiac_resynchronization_therapy_device_management&oldid=1744950"